ACOMPLIA

Buy Online with Prescription Free - Click Here!

About ACOMPLIA: Acomplia contains Rimonabant, the long awaited breakthrough drug by Sanofi for the treatment of obesity and smoking cessation. Advertised in America as Zimulti.

Acomplia represents one of the latest and indeed a most novel method for controlling body weight. It operates by being a cannabinoid receptor antagonist. This means that it prevents the normal action of endogenous cannabinoid in the brain from stimulating the so-called CB1 receptors. It would appear that these receptors stimulate appetite and therefore when they are subdued so is the need to eat.

With specific regard to weight loss, the human trials have shown an average weight loss of 10% of bodyweight, most importantly that weight has remained off even up to 2-years later. Also importantly, it would appear that the majority of weight is actually lost from the difficult to lose area around the waist. The average figures from the trials show a loss of fat of 20 lbs (9 Kg) and 3 inches (8 cm) diameter taken off the waist.

Acomplia has also been shown to improve HDL (good cholesterol), cardiovascular factors such as cholesterol ratios and triglyceride levels, showing benefit for diabetes and heart conditions by subduing receptors which stimulate appetite.

Acomplia Effects - Despite having strengths like weight reduction and increasing good cholesterol numbers the FDA has not acted regarding the approval of the drug as yet. Like all drugs acomplia too is not free from the health risks and side effects. It has certain disadvantages as well, the most dreadful of which is that Acomplia showed about 2.7 fold higher brain disorder rate in a clinical trial among the patients treated with Acomplia v/s the patients with placebo. In a presentation at the Annual Metabolic Diseases Drug Discovery World Summit, Sanofi-Aventis threw light on the latest industry and academic advancements by the leading concerns engaged in the study of obesity and diabetes. At this world summit the company addressed the role of Acomplia in clinical development in disorders related to obesity.

Prescription Free

20mg 28 Tabs 20mg 56 Tabs

Sanofi Aventis Acomplia contains Rimonabant, the long awaited breakthrough drug by Sanofi for the treatment of obesity and smoking cessation. Advertised in America as Zimulti.

Acomplia represents one of the latest and indeed a most novel method for controlling body weight. It operates by being a cannabinoid receptor antagonist. This means that it prevents the normal action of endogenous cannabinoid in the brain from stimulating the so-called CB1 receptors. It would appear that these receptors stimulate appetite and therefore when they are subdued so is the need to eat.

With specific regard to weight loss, the human trials have shown an average weight loss of 10% of bodyweight, most importantly that weight has remained off even up to 2-years later. Also importantly, it would appear that the majority of weight is actually lost from the difficult to lose area around the waist. The average figures from the trials show a loss of fat of 20 lbs (9 Kg) and 3 inches (8 cm) diameter taken off the waist.

Acomplia has also been shown to improve HDL (good cholesterol), cardiovascular factors such as cholesterol ratios and triglyceride levels, showing benefit for diabetes and heart conditions by subduing receptors which stimulate appetite.

Acomplia Effects - Despite having strengths like weight reduction and increasing good cholesterol numbers the FDA has not acted regarding the approval of the drug as yet. Like all drugs acomplia too is not free from the health risks and side effects. It has certain disadvantages as well, the most dreadful of which is that Acomplia showed about 2.7 fold higher brain disorder rate in a clinical trial among the patients treated with Acomplia v/s the patients with placebo. In a presentation at the Annual Metabolic Diseases Drug Discovery World Summit, Sanofi-Aventis threw light on the latest industry and academic advancements by the leading concerns engaged in the study of obesity and diabetes. At this world summit the company addressed the role of Acomplia in clinical development in disorders related to obesity.

ACOMPLIA ACOMPLIA ( Rimonabant )

 
 Previous  Next
 

 
Home Page
 
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
 

 
 
Prices for prescription-drug coverage for Medicare recipients are dropping by 4 percent on average across all plans, according to an analysis this week by a health care consulting group. The top two insurers by membership, however, are increasing prices for Medicare Part D, the prescription drug plans sold by private insurers separate from government-funded Medicare, according to an analysis of federal data by Avalere Health AARP MedicareRx Preferred plans offered by UnitedHealth Group are increasing monthly premiums by 14 percent to $39.70 next year from an average of $34.82 this year. UnitedHealth is the top insurer of Part D plans with 4.8 million people enrolled this year, followed by CVS Caremark with 3.4 million and Humana with 2.4 million. UnitedHealth Group has several advantages that may allow the company to raise prices while others are lowering them, said Dan Mendelson, CEO and founder of Avalere Health, a consulting firm that works for health insurers, think tanks and government. "They have a strong level of name and brand visibility with the AARP banner," he said. "I think that they're banking on the relative unwillingness or inability of seniors to shop aggressively. If people are happy with a health care product, they are often willing to sustain pricing increases. I think what's different here is that there are a range of plans gunning for that top position." UnitedHealth spokesman Matthew Burns said the company dropped its premiums last year by $5, or 12 percent, on its Part D Preferred plans. Premiums in 2012 are slightly lower than they were in 2010, and the company boasts coverage of more branded drugs than other competitors, Burns said. Advocates for Medicare recipients consistently suggest that people look carefully over Part D plans to make sure they drugs they need are covered in the plan they pick. Besides greater competition driving down price, Medicare Part D costs to insurers are expected to drop as the patents on some prescription drugs expire this year and next, allowing doctors to use less expensive generics instead.
 
 
 
 Ј

Copyright © 2011 | No Prescription, Map  
Bonus Pills  Pharmacy No Prescription  Florsheim  Footwear  Lights 
Pony Shoes  Pet Food Barnet  Furniture  online pharmacy  Kitchen Brands  Shannon Elizabeth